ADMA ADMA Biologics Inc

3.63
0  0%
Previous Close 3.63
Open
Price To Book 21.35
Market Cap 215,323,636
Shares 59,317,806
Volume 7,825
Short Ratio
Av. Daily Volume 1,033,938

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA Approval announced April 1, 2019.
RI-002
Primary Immune Deficiency Diseases
Response to Complete Response Letter submitted January 7, 2019.
BIVIGAM
Primary humoral immunodeficiency

Latest News

  1. ADMA Biologics: Selloff Creates Buying Opportunity
  2. SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating ADMA Biologics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
  3. ADMA Biologics Is De-Risked and Ready to Rise
  4. ADMA Biologics to Present at Upcoming Investor Conferences
  5. These 3 Biotech Stocks Are Attracting Insider Buying
  6. ADMA Biologics Announces Closing of $51.75 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
  7. Adma Biologics Inc (ADMA) President and CEO Adam S Grossman Bought $120,000 of Shares
  8. NeuBase Therapeutics Designates Industry Leaders to Board of Directors 
  9. ADMA Biologics Announces Proposed $45 Million Public Offering of Common Stock
  10. FDA Approves Prior Approval Supplement for BIVIGAM®
  11. Adma Biologics: 1Q Earnings Snapshot
  12. ADMA Biologics Reports First Quarter 2019 Financial Results
  13. ADMA Biologics Granted U.S. Patent for Treatment and Prevention of Pneumococcal Infections
  14. ADMA Biologics: Wall Street Projects Robust Revenue Growth
  15. Why ADMA Biologics Stock Soared Yesterday
  16. The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings
  17. ADMA Receives Department of Health and Human Services U.S. License
  18. ADMA Biologics Rips Higher On FDA Nod For Immunodeficiency Therapy
  19. ADMA Biologics' stock rockets on heavy volume after FDA approval of immunodeficiency treatment